Inhibitory effect of farnesylthiosalicylic acid on mediators release by mast cells: Preferential inhibition of prostaglandin D 2 and tumor necrosis factor-α release

Inflammation

Volumn 34, Issue 5, 2011, Pages 314-318

  Mor, Adam ^a,b   Ben Moshe, Ofer ^a   Mekori, Yoseph A ^a   Kloog, Yoel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Farnesylthiosalicylic acid; Mast cell; Tumor necrosis factor

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; CYTOKINE; IMMUNOGLOBULIN E; PROSTAGLANDIN D2; RAS PROTEIN; SALIRASIB; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAST CELL DEGRANULATION; MEDIATOR RELEASE; MOUSE; NONHUMAN; PROSTAGLANDIN RELEASE; PROTEIN SECRETION; SKIN ALLERGY; SKIN ANAPHYLAXIS;

ANIMALS; CELL DEGRANULATION; CELL LINE; FARNESOL; FEMALE; HUMANS; MAST CELLS; MICE; MICE, INBRED BALB C; PASSIVE CUTANEOUS ANAPHYLAXIS; PROSTAGLANDIN D2; RAS PROTEINS; SALICYLIC ACIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80655135443     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-010-9236-x     Document Type: Article

References (7)

1. Blum, R., and Y Kloog. 2005. Tailoring Ras pathway-inhibitor combinations for cancer therapy Drug Resistance Update 8: 369-380. (Pubitemid 43358060)
2. Pando, R., I. Barshack, A. Raz, G. Luboshits, R. Haklai, S. Maysel-Auslender, Y Kloog, G. Keren, and J. George. 2010. The Ras antagonist farnesylthiosalicylic acid ameliorates experimental myo-carditis in the rat. Cardiovascular Pathology 19: 94-101.
3. Matcalfe, D.D., R.D. Peavy and A.M. Gilfillan. 2009. Mechanisms of mast cell signaling in anaphylaxis. The Journal of Allergy and Clinical Immunology 124: 639-646.
4. Shefler, I., YA. Mekori, and A. Mor. 2008. Stimulation of human mast cells by activated T cells leads to N-Ras activation through Ras guanine nucleotide releasing protein 1. JAllergy Clin Immunol 122: 1222-5.
5. Baram, D., M. Rashkovsky R. Hershkoviz, I. Drucker, T. Reshef, S. Ben-Shitrit, and YA. Mekori. 1997. Inhibitory effects of low molecular weight heparin on mediator release by mast cells: preferential inhibition of cytokine production and mast cell-depend-ent cutaneous inflammation. Clinical and Experimental Immunology 110: 485-491. (Pubitemid 27525283)
6. Sicherer, S.H., and D.YM. Leung. 2010. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2009. The Journal of Allergy and Clinical Immunology 125: 85-97.
7. Mor, A., I. Shefler, P. Salamon, Y Kloog, and YA. Mekori. 2010. Characterization of ERK activation in human mast cells stimulated by contact with Tcells. Inflammation 33: 119-125.